Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: The RESOLVD pilot study investigators

Circulation

Volumn 100, Issue 10, 1999, Pages 1056-1064

  McKelvie, R S ^a,i   Yusuf, S ^a   Pericak, D ^a   Avezum, A ^b   Burns, R J ^c   Probstfield, J ^d   Tsuyuki, R T ^e   White, M ^f   Rouleau, J ^f   Latini, R ^g   Maggioni, A ^g   Young, J ^h   Pogue, J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^f MONTREAL HEART INSTITUTE   (Canada)

^g MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

Cardiac volume; Heart failure; Natriuretic peptides

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; ENALAPRIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE TOLERANCE; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 0033533456     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.10.1056     Document Type: Article

References (16)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 326:1429-1435.
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
3. Rouleau JL, Kortas C, Bichet C, de Champlain J. Neurohumoral and hemodynamic changes in congestive heart failure: lack of correlation and evidence of compensatory mechanisms. Am Heart J. 1988;116:746-757.
4. Timmermans PBMWM, Duncia JV, Carini DJ, Chiu AT, Wong PC, Wexler RR, Smith RD. Discovery of losartan, the first angiotensin II receptor antagonist. J Hum Hypertens. 1995;9(suppl 5):S3-S18.
5. McDonald KM, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A, Cohn JN. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation. 1995;91: 2043-2048.
6. Tsuyuki RT, Yusuf S, Rouleau JL, Maggioni A, McKelvie RS, Wiecek EW, Wang Y, Pogue J, Teo KK, White M, Avezum A, Latini R, Held P, Lindgren E, Probstfield J, for the RESOLVD Pilot Study Investigators. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol. 1997;13: 1166-1174.
7. Rector TS, Kubo SH, Conn JN. Validity of the Minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol. 1993;71:1106-1107.
8. Dickstein K, Chang P, Willenheimer R, Haunsø S, Remes J, Hall C, Kjekshus J. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 1995;26:438-445.
9. Lang RM, Elkayam U, Yellin LG, Krauss D, McKelvie RS, Vaughan DE, Ney DE, Makris L, Chang PI, on behalf of the Losartan Pilot Exercise Study Investigators. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. J Am Coll Cardiol. 1997;30:983-991.
10. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI, on behalf of ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752.
11. Hamroff G, Blaufarb I, Mancini D, Katz SD, Bijou R, Jondeau G, Olivari M-T. Thomas S, LeJemtel TH. Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure. J Cardiovasc Pharmacol. 1997;30:533-536.
12. Spinale FG, de Gasparo M, Whitebread S, Hebbar L, Clair MJ, Melton DM, Kromback RS, Mukherjee R, Iannini JP, O SJ. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure, I: effects on left ventricular performance and neurohormonal systems. Circulation. 1997;96: 2385-2396.
13. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Niclas J, Liang C-S, Kubo SH, Rudin-Toretsky E, Yusuf S, for the SOLVD Investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation. 1990; 82:1724-1729.
14. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730-1736.
15. Crozier I, Ikram H, Arvan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, Rucinska E, for the Losartan Hemodynamic Study Group. Losartan in heart failure: hemodynamic effects and tolerability. Circulation. 1995;91:691-697.
16. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, Dekock M. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993;88(pt 1):1602-1609.